SGMO News and Press, Sangamo Therapeutics Inc. From 03/17/25

Continued to advance our prioritized neurology genomic medicine pipeline towards the clinic. Announced two neurology license agreements with blue-chip pharma companies, including a global epigenetic regulation and capsid delivery license agreement with Genentech in August 2024 to develop ...

2025-03-17 10:00:00 ET Major earnings expected after the bell on Monday include: Lithium America Corp. ( LAC ) Sangamo Therapeutics ( SGMO ) Eastman Kodak Company ( KODK ) High Tide ( HITI ) FibroGen ( FGEN ) Read the full article on Seeking...

Eyenovia Inc. (EYEN) is expected to report $-8 for Q4 2024 Nemaura Medical Inc. (NMRD) is expected to report for quarter end 2024-12-31 LanzaTech Global Inc. (LNZA) is expected to report $-0.16 for Q4 2024 Investcorp Credit Management BDC Inc. (ICMB) is expected to report for Q2 2025 ...

2025-03-16 09:47:00 ET Summary In a volatile fourth quarter, the Wasatch Ultra Growth Fund—Investor Class returned 0.94% and slightly underperformed the benchmark Russell 2000® Growth Index, which rose 1.70%. Equities rallied following the November elections on hopes t...

2025-03-16 08:00:19 ET More on related stocks XPeng Earnings Preview: Stock Value Rising On A Key Breakthrough Bet Micron: Capitalizing On The Prolonged Memory Cycle General Mills Is A Solid Long-Term Investment With Upside Potential China's Xpeng to spend up...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2024 financial results after the markets close on Monday, March 17, 2025. The company also plans to participate in an upcoming inves...

2025-03-05 21:04:00 ET Summary For the fourth quarter of 2024, the Wasatch Micro Cap Fund— Investor Class returned 2.61%, and underperformed the benchmark Russell Microcap® Growth Index, which returned 11.55%. During the quarter, U.S. equities gained ground after the U...

2025-03-02 08:00:41 ET As Wall Street steps into March, the earnings schedule offers a look at how a broad range of industries are navigating the current economic landscape.... Read the full article on Seeking Alpha For further details see: Earnings week ahead: TGT, COST, CR...

2025-02-11 00:13:38 ET Summary Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data, following a pattern of big pharma partners ending collaborations. Current hemophilia A market shows poor commercial potential, with BioMarin's simi...

2025-02-06 13:56:32 ET More on Sangamo Therapeutics Sangamo Therapeutics: Left At The Altar (Rating Downgrade) Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript Why d...